Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-human safety, pharmacokinetics, and pharmacodynamics study of KLR-003
NL-OMON61097Phase 1Recruiting
- Sponsor
- Klear Bio
- Start
- May 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 1 trial of KLR003 in psoriasis and autoimmune inflammatory diseases, sponsored by Klear Bio. Started May 2026; status: recruiting.
02
Drugs
KLR003
03
Conditions
psoriasisautoimmune inflammatory diseases
Beyond the preview
Go deeper on NL-OMON61097.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON61097.